Document r4z95eqJb90Vb0y2KY60vQoe

Larry R. Zobel, MD, MPH Staff Vice President and Medical Director 3M Medicai Department 3M Center, Building 220-2E-02 PO Box 33220 St. Paul, MN 55133-3220 651 733 5181 Office 651 733 5152 Facsimile Aprii 25,2000 Dr. Oscar Hernandez US EPA/OPPT/CCD (7405) 401 M Street, SW Room E615B Washington, DC 20460 VIA FEDERAL EX PRESS Fec*Numbs. O 'C u sto m - fu d E iO ''*'1'9- Mnf Dear Dr. Hernandez: Enclosed are copies of the following documents which were inadvertently omitted from our package sent to you last Friday, April 21, 2000: 1. Protocol 418-008 Combined oral (gavage) fertility, developmental and perinatal/postnatal reproduction toxicity study of PFOS in rats (Sponsor's study number: 6295.9), Table E20, 1-3; 2. Harb, R.V., Hartman, H.A. and Cox, R.H. (1994), Prevention o f fluvastatin induced toxicity, mortality, and cardiac myopathy in pregnant rates by mevalonic acid supplementation. Teratology, 50, 19-26; 3. Haughom, B. and Spydevold, 0 . (1992), The mechanism underlying the hyperlipemic effect of perfluorooctanoic acid (PFOA), perfluorooctate sulphonic acid (PFOS) and clofibric acid. Biochimica et Biophysica Acta, 1128,65-72; 4. Levin, M.S. Pitt, A.J.A., Schwartz, A.L., Edwards, P.A. and Gordon, J.I. (1989), Developmental changes in the expression of genes involved in cholesterol biosynthesis and lipid transport in human and rat fetal and neonatal livers. Biochimica et Biophysica Acta, 1003, 293-300; and 5. Interoffice memo from Tom Kestner to Leo Gehlhoff, "Fluorochemical Isomer Distribution by 19F-NMR Spectroscopy," December 1,1997. If you have any questions or need additional information, please feel free to contact me at 651-733-5181. Sincerely, -arry R. Zobel, MD MPH Staff Vice President & Medical Director LRZ:kmj Enclosures